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  Cytochrome P450 enzymes use a variety of molecules as substrates in enzymatic reactions, mostly catalysing 
oxidation of these substrates. Some of the enzymes activate carcinogenesis, including breast cancer develop-
ment. The purpose of the present paper is to review and discuss the interactions between food products and 
substrates metabolized by enzymes of the cytochrome P450 in relation to the development of breast cancer.
  A review of recently published papers was undertaken.
  Electronic searches on nutrients, cytochrome P450, and breast cancer were performed on PUBMED, MEDLINE, 
EMBASE, and EBSCO in March 2018.
  Molecular and clinical studies indicate that diet-cytochrome P450 interactions affect the risk for developing 
breast cancer. However, these are early results which are limited and frequently not reproducible due to pos-
sible information bias in food frequency questionnaires. Based on a review of available literature, food prod-
ucts interacting with substrates metabolized by the enzymes of the cytochrome P450 and thus having a direct 
or indirect effect on breast cancer development were identified.
  Nutrition plays an important role in breast carcinogenesis. Eating foods which modify the activity of certain 
cytochrome P450 enzymes such as CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP3A4, CYP19A1, and CYP24A1 can 
contribute to prevention of breast cancer. Diet can act as an adjuvant in the treatment of this disease. Further 
studies are needed to elucidate the role of nutrients regularly consumed in the development of breast cancer, 
specifically their effect on substrates metabolized by the cytochrome P450 enzyme family and the correspond-
ing mechanisms.
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Background
The human cytochrome P450 enzymes (CYP450) catalyze ox-
idative reactions of a broad spectrum of substrates and play 
a critical role in the metabolism of xenobiotics, such as drugs 
and dietary bioactives. Cytochrome P450 first modifies a com-
pound, usually by the addition of oxygen, to make it more po-
lar and hence easier to excrete. This modification can lead to 
reactive or unstable metabolites that can react further with 
neighboring proteins or glutathione or rearrange to form new 
products [1]. In humans, there are 57 genes coding for cyto-
chrome P450 enzymes and more than 59 pseudogenes dis-
tributed in 18 families and 43 subfamilies. The most impor-
tant families for humans are: CYP1, CYP2, CYP3, CYP4, CYP5, 
CYP6, CYP7, CYP8, CYP11, CYP17, CYP19, CYP20, CYP21, CYP24, 
CYP26, CYP27, CYP39, CYP46, and CYP51. Numerous drugs are 
metabolized by these isoenzymes [2].
At present, scientific research on breast cancer is flourishing. 
The estimated number of new cases of female breast cancer 
is 124.9 per 100 000 women per year. The survival rate in 5 
years is 90%, due to treatment advances in recent years [3].
It is well known that genetics have an important impact on 
the development and progression of cancer. HER2 (human epi-
dermal growth factor receptor 2) is a growth-promoting pro-
tein on the outside of all breast cells. Breast cancer cells with 
higher than normal levels of HER2 are called HER2-positive. 
These cancers are inheritable and tend to grow and spread 
faster than other breast cancers [4]. Research evidence sup-
ports the idea of a significant interaction between nutrition 
and genomics, in which diet influences gene expression and 
metabolic responses. However, the interactions can sometimes 
have a negative impact on health, increasing susceptibility to 
diet-dependent diseases. Nutrients affect, among others, the 
catalytic cycles and metabolic pathways related to the cyto-
chrome P450 enzymes [5].
Cytochrome P450 enzymes use a variety of small and large 
molecules as substrates in enzymatic reactions, mostly cata-
lysing oxidation of these substrates. Some of the enzymes that 
activate carcinogenesis are CYP1A1, CYP1A2, CYP1B1, CYP2A6, 
CYP2B6, CYP2E1, and CYP3A4/5/7 [6,7].
One of the treatments for breast cancer is the modulation of 
estrogen exposure via ovarian ablation, surgery, irradiation, 
or medication. Some of the medications available are inhib-
itors of estrogenic receptors (ER), downregulating ERs or de-
creasing estrogen production by aromatase inhibitors, such 
as Anastrozole or Letrozole, or by selective estrogen recep-
tor modulators (SERM) with tissue-specific activities, such as 
Tamoxifen or Clomiphene. Oral chemotherapy is associated with 
a significant number of medication and food interactions. It 
is essential that a patient’s diet and concurrent medications 
are thoroughly evaluated by healthcare professionals to pro-
vide accurate patient education, therapeutic monitoring, and, 
if necessary, alternative recommendations, whenever oral che-
motherapy is prescribed [8]. The mechanism of action of most 
drugs that act against breast cancer include the interaction 
with a CYP450 enzyme, which makes the cytochrome a ther-
apeutic target. The main target in the case of breast cancer is 
the aromatase enzyme encoded by CYP19, which is respon-
sible for catalysing the biosynthesis of estrogens. The most 
biologically active estrogen in breast tissue is 17b-estradiol 
(E2). However, most women develop post-menopausal breast 
cancer, when plasma levels of E2 have decreased by 90% due 
to ovarian exhaustion. Thus, the uptake of E2 from the circu-
lation does not appear to contribute significantly to the to-
tal content of estrogen in breast tumors. It has been demon-
strated that breast tumors and mammary cancer cells possess 
CYP19A1 necessary for the intra-tumour biosynthesis of estro-
gens from precursor molecules circulating in the plasma [9]. 
Thus, the neoplasm induces a local production of aromatase, 
which increases the effectiveness of aromatase inhibitors in 
the treatment of breast cancer.
It has been proven that the inhibition of aromatase enzyme 
reduces estrogen production, thus decreasing the odds for 
the potential development of hormone-responsive breast 
cancers [6,10].
The use of complementary medical treatment such as diet and 
nutritional supplements for women with a previous history of 
breast cancer is increasingly favored to enhance the action of 
drugs and reduce their adverse effects.
Moreover, the antioxidant effect of some foods provides an ad-
ditional benefit. Uncontrolled production of free radicals (rad-
ical oxygen-derived species (ROS)) can lead to an increase in 
mutagenesis in the cells and thus the development of cancer. 
This production of ROS is mediated by a reaction of oxidation 
resulting in a variety of inflammatory responses. Normally, 
cells can defend and protect themselves by producing enzymes 
such as superoxide dismutase and catalase. In the same way, 
small molecules such as polyphenols, vitamin C, allopurinol, 
and uric acid have antioxidant activity. Eating foods with an-
tioxidant properties may have a preventive effect on the de-
velopment of breast cancer.
Cytochrome P450 mechanism
The cytochrome P450 constitutes a large superfamily of en-
zymes that catalyse the oxidative transformation of organ-
ic substrates (Figure 1). This superfamily of enzymes plays 
a key role in xenobiotic metabolism and steroid transforma-
tion in humans. Activities of the cytochrome P450 enzymes 
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can be affected by diverse genetic and environmental factors 
that render their metabolism variable. This variability poses a 
challenge for drug development, which generally targets the 
inhibition of specific cytochrome P450 enzymes. Inhibition can 
lead to an increased bioavailability or a decreased elimina-
tion of compounds, resulting in a high blood level (Figure 2). 
However, exogenous compounds can also induce the activity 
of cytochrome P450 enzymes (Figure 3). In such conditions, 
the cytochrome P450 enzymes can metabolize a variety of xe-
nobiotics faster (Figure 4) [6,7,11,12].
The aim of the present review was to gather scientific infor-
mation about how nutrition can interact with substrates me-
tabolized by the enzymes of cytochrome P450, thus modifying 
its activity and thereby affecting breast cancer development. 
The clinical applicability of diet as an adjuvant relevant to the 
treatment of breast cancer is discussed.
Material and Methods
The review strategies, including the search and selection of 
the articles, are based on guidelines of the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) [13].
Sources and research strategy
We performed a literature search using PubMed, EBSCO, EMBASE, 
Medline, and other sources such as the American Cancer Society 
and the National Cancer Institute, for articles published in English. 
The studies were related to the influence of nutrients on cyto-
chrome P450 and how diet can affect the development of breast 
cancer. The following MeSH terms and research terms were used: 
“Breast cancer”, “Breast cancer and nutrition”, “Nutrients and cy-
tochrome P450”, “Cytochrome P450 and breast cancer”, “nutri-
tion and cancer”, “cytochrome P450 substrates”, “natural aroma-
tase inhibitors”, “Risk factors for breast cancer”, “Complementary 
therapies and breast cancer”, and “Nutrition and genomics”.
Eligibility criteria
The literature research yielded 2954 bibliographic records only 
in the first research with “((breast cancer) AND cytochrome 
Inactive metabolites
Inactivation Activation
Excretion
Active metabolitesIsoenzymescytochrome P450
XENOBIOTICS
Binding to
macromolecules
Carcinogenesis
Mutagenesis
Cell damage
Figure 4.  Outline of the mechanisms of 
CYP450 enzymes [adapted from 
23]. An example of activation is the 
metabolism of codeine to morphine 
by CYP2D6. Morphine is a very active 
metabolite. Codeine cannot serve as 
analgesic medicine in patients who 
cannot or can only slowly metabolize 
codeine to morphine. Meanwhile, 
most of the tricyclics drugs used in 
mental diseases suffer a process of 
inactivation and produce inactive 
metabolites (except for a few 
substrates such as imipramine, which 
is metabolized to desipramine (active 
metabolite)).
Figure 1. CYP450 (cytochrome P450) with a substrate (S).
Figure 3. CYP450 with an enhancer (En)
Figure 2. CYP450 with an inhibitor (Inh).
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P450)” keywords and 5307 with “(cytochrome P450) AND nu-
trients”. First, duplicates were identified and removed from the 
pool of bibliographic records. Next, accurate screening of ab-
stracts and titles was performed to determine the most rele-
vant articles. Afterwards, full articles were reviewed using the 
following inclusion criteria: (1) studies providing information 
about the relationship between nutrition and breast cancer; 
(2) studies explaining the metabolic pathways of cytochrome 
P450 enzymes; (3) studies explaining how some nutrients inter-
act with substrates metabolized by cytochrome P450 enzymes; 
(4) studies providing clinical information about the pathogen-
esis of breast cancer; (5) studies providing information about 
any cytochrome P450 enzyme. In conclusion, 52 studies were 
retained; these were mostly recent studies, but also included 
some earlier studies presenting analyses that were not found 
in the most recent studies.
Results
CYP450 enzymes in breast cancer
Several scientific articles have been analysed to determine which 
cytochrome P450 enzymes have a significant effect on breast 
cancer development. It has been shown that cytochrome P450 
polymorphisms play an important role in the metabolic activation 
CYP450 enzymes
Food products CYP1A1 CYP1B1 CYP2B6 CYP3A4 CYP19A1 CYP24A1
Pu
re
 s
ub
st
an
ce
Caffeine – – – S 0 –
Calcitriol (Vit D) – – – – 0 0
Cocoa 0 – – – 0 –
Curcumin 0 – 0 0 – –
Dietary lipids 0 0 – – – –
Ellagitannins – – – – 0 –
Estrogens – 0 – – 0 –
Ethanol – – – – 1 –
Flavonoids 0 0 – – 0 –
Ginseng – – – 0 – –
Green tea – – – – 0 –
Mangosteen – – – – 0 –
Monoterpenes – – – – 0 –
Polyphenols – – – 0 0 –
Resveratrol – – – 0 0 –
St. John’s wort – – – 1 – –
Sp
ic
es
Black pepper 0 – – 0 – –
Cardamom 0 – – – – –
Cinnamon 0 – – 0 – –
Ginger 0 – – 0 – –
Nutmeg – – – 0 – –
Saffron 0 – – – – –
White pepper – – – 0 – –
Table 1.  Food-cytochrome P450 enzymes interactions which influence breast cancer development 0=inhibitor; 1=enhancer; 
S=substrate
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of procarcinogens [6,7,11,12]. However, only a few of these en-
zymes have a direct impact in breast cancer, like CYP1A1, CYP1A2, 
CYP1B1, CYP2B6, CYP3A4, CYP19A1, and CYP24A1 (Table 1).
Analysis of the influence of nutrients on substrates 
metabolized by CYP450
As depicted in Table 1, many food products interact with sub-
strates metabolized by cytochrome P450 enzymes, thereby af-
fecting the development of breast cancer. Most of them can 
be inhibitors, which means they decrease the metabolic func-
tion of the cytochrome P450 enzyme they interact with. A few 
nutrients are enhancers or substrates.
Food products playing an important role in the cytochrome 
P450 metabolism were classified by category: Pure substanc-
es, spices, vegetables, drinks, cereals, and meat.
Pure substances
Caffeine acts as an inhibitor for the CYP19A1 enzyme and as a 
substrate for CYP3A4 and CYP1A2 [14]. Calcitriol (vitamin D) is 
an inhibitor of CYP19A1 [12] and CYP24A1 [15]. Also, cocoa is 
an inhibitor of CYP19A1 and CYP1A1 [16]. Curcumin is a 1A1, 
2B6, and 3A4 inhibitor [17]. Dietary lipids are also inhibitors 
for CYP1A1 and 1B1 [18]. Ellagitannins inhibit CYP19A1 [9]; es-
trogens are physiological substrates of CYP19A1 and inhibit 
CYP1B1 [9]; flavonoids inhibit 1A1, 1B1, and 19A1 [47,49]; gin-
seng inhibits 3A4; and green tea, mangosteen, and monoter-
penes inhibit CYP19A1 [9]. Glycyrrhizin acid inhibits CYP1A2, 
2B6, and 3A4 and enhances 19A1 [21,22]. Polyphenols and 
resveratrol inhibit 3A4 and 19A1 [23]. However, ethanol acts 
as an enhancer of CYP19A1 and St John’s wort is an enhanc-
er of CYP3A4 [18,24].
CYP450 enzymes
Food products CYP1A1 CYP1B1 CYP2B6 CYP3A4 CYP19A1 CYP24A1
Ve
ge
ta
bl
es
Broccoli – – – – 0 –
Brussel sprouts – – – – 0 –
Cauliflower – – – – 0 –
Garlic 0 – – – 0 –
Grapefruit – – – 0 0 –
Grapseed – – – – 0 –
Mushrooms – – – – 0 –
Onion 0 – – – – –
Starfruit – – – 0 – –
Soy – – – – 0 –
Thistle – – – 0 – –
Tomato – – – 0 0 –
D
ri
nk
s
Beer – – – 0 – –
Cabbage juice – – – – 0 –
Pomegranate juice – – – 0 – –
Ce
re
al
s
Buckwheat – – – – 0 –
Millet – – – – 0 –
Rice – – – – 0 –
M
ea
t Grilled meat 0 0 – 0 – –
Smoked meat 0 0 – 0 – –
Table 1 continued.  Food-cytochrome P450 enzymes interactions which influence breast cancer development 0=inhibitor; 1=enhancer; 
S=substrate
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Spices
Black pepper, cinnamon, and ginger are inhibitors of CYP1A1 
and CYP3A4. Cardamom and saffron only inhibit CYP1A1, and 
nutmeg and white pepper only inhibit CYP3A4 [20,26].
Vegetables and fruits
Most of the vegetables listed in Table 1 inhibit CYP19A1, in-
cluding broccoli, brussels sprouts, cauliflower, grapeseed, 
mushrooms, and soy, but broccoli and brussels sprouts are 
enhancers of CYP1A2. Grapefruit and tomato inhibit CYP3A4 
in addition to inhibiting CYP19A1. Garlic is also an inhibitor of 
1A1 and 19A1. Starfruit and thistle only inhibit CYP3A4, and 
onion only inhibits CYP1A1 [9,25,26].
As CYP3A4 metabolizes 80% of all substrates, when a nutri-
ent enhances it, the other enzymes involved in carcinogenesis 
have fewer substrates available. Therefore, enhancing CYP3A4 
might prevent carcinogenesis.
Drinks
Drinks such as beer and pomegranate juice inhibit the 
CYP3A4 enzyme [25,26]. Cabbage juice inhibits the 19A1 en-
zyme [27–30].
Cereals
Buckwheat, millet, and rice inhibit the CYP19A1 enzyme 
[9,25,26].
Meat
Some studies reported that grilled and smoked meat can in-
hibit the CYP1A1, 1B1, and 3A4 enzymes but are enhancers 
of CYP1A2, which can increase its activity up to 40-fold [31]. 
The enzymes of CYP1, CYP2, and CYP3 are unspecific, which 
is why they are influenced differently by nutrients and their 
effect is difficult to predict.
Influence of polyphenols inhibiting CYP19A1 enzyme
Polyphenols are bioactive chemical compounds present in 
various foods and beverages and chemically characterized by 
having 1 or more hydroxyl groups attached to their phenolic 
groups. Most of the above-mentioned food products are very 
rich in polyphenols. Numerous studies show that a diet rich 
in polyphenols, within the framework of balanced nutrition, 
has numerous beneficial effects on health. Polyphenols play 
a very important role in decreasing inflammatory processes 
and oxidative stress. These 2 metabolic processes relate to the 
incidence of chronic diseases such as diabetes, certain types 
of cancer, and obesity. The concomitant cellular stress that 
is generated in these diseases is accompanied by an altered 
metabolic and inflammatory response in multiple cell types.
One of the isoenzymes on which polyphenols have a signifi-
cant effect is aromatase (CYP19A1). Table 2 shows the strength 
with which subgroups of polyphenols inhibit CYP19A1 en-
zyme [25,26].
Antioxidant capacity of polyphenols and other health 
benefits
The protective effect of polyphenols is partly due to their high 
antioxidant capacity. Antioxidants are chemical compounds 
that promote the elimination from our body of free radicals 
ROS and waste compounds generated from certain metabolic 
functions. From a nutritional point of view, an adequate and 
regular intake of antioxidants is one of the best ways to re-
duce the relative risk of chronic diseases such as cancer. Some 
studies suggest that high overall dietary antioxidant capacity 
is associated with a lower risk of breast cancer [32]. For exam-
ple, low intake of carotenoids is associated with higher risk of 
breast cancer among smokers and low intake of flavonoids is 
associated with breast cancer risk in women over the age of 
70 [32]. In addition, an inverse relationship between antiox-
idant levels and the concentration of plasma C-reactive pro-
tein, a molecule that is elevated in the processes that occur 
with inflammation, has been demonstrated [33–35].
In addition to the antioxidant capacity of polyphenols, it is im-
portant to note that substances such as flavonoids, the larg-
est family of polyphenolic compounds, can modulate signal 
pathways, promoting a whole series of beneficial effects on 
cells, and thus affecting the different organs and the body as 
a whole [22,33–36].
Discussion
Several food products affect substrates that are metabolized 
by cytochrome P450 enzymes. Most of these foods appear to 
modulate the catalytic activity of a few cytochrome P450 en-
zymes. The main finding is that natural products can modu-
late cytochrome P450 enzymes in the same way that drugs do. 
Some enzymes, such as CYP1, CYP2and CYP3, are unspecific, 
so they can be influenced differently by nutrients and their ef-
fect is difficult to predict. Therefore, nutrition is a very power-
ful tool to modify cytochrome P450 enzymes and prevent the 
development of diseases such as breast cancer. Table 1 shows 
which food products influence metabolism of cytochrome 
P450 enzymes. Most food products that play an inhibitor role 
contain polyphenols. Polyphenols can be subdivided into fla-
vonoids (such as tannins, flavones, flavanones, isoflavones, 
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Table 2.  Strength with which different types of polyphenols and biological compounds inhibit aromatase (CYP19A1) [adapted from 23].
Subgroup Name Inhibition CYP19A1
Chalcones
Naringenin chalcone Strong
Eriodictyol chalcone Strong
2,4,2’,4’-tetrahydroxy-3’ prenylchalcone Strong
3’-[y-Hydroxymethyl-(E)-y-methyallyl]-2,4,2’,4’-tetrahydroxychalcone 11’-
O- coumarate
Strong
Isogemichalcone C Moderate
Flavanones
Naringenin Moderate
Hydroxyflavanone Moderate
7-methoxyflavanone Moderate
7-hydroxiflavanone Strong
Hesperetin Strong
Eriodictyol Strong
8-Prentlnaringenin Strong
Isoflavans
4’-O-Methyglabridin Weak
Leiocin Weak
Leiocinol Weak
Methylequol Weak
Flavonoids
Chrysin Strong
Apigenin Strong
Quercetin moderate
Miscellaneous 
flavonoids
Coumesterol Weak
Rotenone Strong
Flavones
Flavone Weak
7-hydroxyflavone Strong
Luteolin Strong
7,8-dihydroxyflavone Strong
Isolicoflavonol Strong
7,4-hydroxiflavone Strong
Broussoflavonol F Moderate
Methoxyflavone Moderate
Rutin Moderate
Catechins
Epigallocatechin gallate Weak
Theaflavin Strong
Theaflavin-3,3’-gallate Strong
Gallocatechin gallate Weak
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catechins, lignans, stilbenoid, and anthraquinones) and oth-
er bioactives not derived from flavonoids. Table 2 shows the 
strength with which each of these subgroups inhibits the ac-
tivity of the CYP19A1 enzyme (aromatase) [37].
Aromatase is responsible for a key step in the biosynthesis of 
estrogens – it transforms androstenedione into estrone and 
testosterone into estradiol. Estrogens promote the develop-
ment of some cancers, including breast cancer, so the inhib-
itors of aromatase are commonly used to treat these diseas-
es [38]. Therefore, to reduce the levels of steroid hormones in 
the body, aromatase inhibitors could be used to inhibit the re-
action. Not all aromatase inhibitors are equally effective, since 
those with more structural similarity have more affinity to the 
receptors. Thus, aromatase inhibitor stereochemistry is essen-
tial to determine the effect it will have on the development 
of breast cancer. The quantities used have a large impact on 
the effect produced. The neoplasm induces local production 
of aromatase, which increases the effectiveness of aroma-
tase inhibitors in the treatment of breast cancer. When using 
aromatase inhibitors, estrogen levels decrease in the plasma 
and locally, mainly in breast “hot spots”, decreasing the out-
break or progression of breast cancer. In addition to the phar-
macochemical aromatase inhibitors, there are many natural 
components that can perform the same action, most likely 
with fewer adverse effects.
Polyphenols, for example, are natural aromatase inhibitors. 
By simply ingesting products that contain these components, 
the development of breast cancer could be slowed and even 
be prevented. They have a double-anticancer action. On the 
one hand, they induce blockage of the cell cycle of the can-
cer cells, inducing apoptosis, and on the other hand, they in-
duce the synthesis of detoxification enzymes. Other benefits 
of polyphenols include cardiovascular prevention, effects on 
the immune system, and anti-infective effects [23,36]. It is dif-
ficult to estimate the quantity of polyphenols needed to pre-
vent breast cancer and which enantiomers have an effect, but 
it was reported that the tumorigenic potential of cancer cells 
was significantly diminished at concentrations between 50 and 
Subgroup Name Inhibition CYP19A1
Lignans
Enterolactone Moderate
Norhydroguaiaretic acid Weak
4,4’-dihydroxyenterolactone Moderate
Fatty acids
(10E, 12Z)-9-oco-10,12-octadecadienoic acid Moderate
(10E,12Z)-9-hydroxy-10,12-octadecadienoic acid Weak
Docosapentaenoic acid Weak
Peptides N-benzoyl-L-phenylalanine methyl ester Weak
Benzenoids TAN-931 Weak
Sesquiterpene 
lactone
11BH,13-dihydro-10-epi-8-deoxycumambrin Strong
deoxycumambrin Moderate
Stilbenoid
resveratrol Strong
Albanol A Moderate
Terpenoids
Standishinal Weak
Ent-kaurane diterpenoid Weak
Aglaiaglabretol B Moderate
(–)-dehydrololiolide Moderate
Xanthones
Mangostin Strong
Garcinone Strong
Anthraquinones Benzanthraquinone I Strong
Table 2 continued.  Strength with which different types of polyphenols and biological compounds inhibit aromatase (CYP19A1) 
[adapted from 23].
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100 µM of E-resveratrol, and curcumin has been shown to in-
hibit the formation of breast cancer mammospheres in vitro 
by 50% and 100% using 5-µM and 10-µM concentrations, re-
spectively. Both products are rich in polyphenols [39]. Also, a 
protein-rich diet including 300 g soy protein corresponds to 
more than 100 g isoflavones per day helps to prevent breast 
cancer. Although the potency of isoflavones is a mere per 
mille of physiological 17b-estradiol, it can significantly modu-
late estradiol effects at the estradiol receptors due to its high 
affinity for the alpha receptor subtype, thus inducing a com-
petitive inhibition. They compete for the a-estrogen receptor, 
and the relative concentrations of estradiol and of isoflavones 
competing for the receptor determine the long-term prophy-
lactic success [40].
Chronic inflammation contributes to the development of can-
cer, not only by pro-inflammatory markers, but also by the ox-
idative stress that it causes. Oxidative stress is the result of 
an imbalance between the production of reactive species and 
the activity of antioxidant defence systems. It has been sug-
gested that biologically older woman developed more aggres-
sive breast cancers than their biologically younger counterparts 
due to the grade of oxidative aging. The amount of reactive 
species seems to be directly related to the risk of breast can-
cer [21]. The endogenous and exogenous antioxidant defenc-
es protect the cells from the oxidative damage caused by the 
released radical products, thereby preventing premature cell 
damage [41]. Food plays a very important role in the appear-
ance of chronic inflammation. Even so, the main mechanism is 
the local activity of aromatase in breast tissue. Changing nutri-
tional habits can help reduce inflammation and thus reduce the 
risk of all forms of cancer, diabetes, and other diseases, even 
if the risk is inherited. Foods that help reduce inflammation 
include fruits, vegetables, whole grains, and legumes [34,35].
The development of specific nutritional guidelines for breast 
cancer based on results such as the ones presented in this 
paper could be a major step forward for diabetes counseling, 
which could thus contribute to the prevention and therapy of 
this disease. The main focus is likely to be on prevention and 
adjuvant pharmacotherapy.
Conclusions
The pathogenesis of breast cancer is complex, but it has been 
suggested that the metabolic pathway of the cytochrome P450 
enzymes plays an important role in the activation and inactiva-
tion of pre-carcinogens, along with inter-individual differences 
and environmental factors. This review article summarizes the 
findings obtained to date concerning food interactions with 
substrates metabolized by the cytochrome P450 isoenzymes 
involved in the development of breast cancer. The presence of 
reactive species from oxidative stress and inflammation great-
ly increases the risk of breast cancer. These processes can be 
targeted with the optimal use of foods with antioxidant and 
anti-inflammatory capacity. This research field is evolving rap-
idly and more information will be available in the near future 
that will help combine drug therapy with dietary counseling 
to optimize treatment of breast cancer.
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